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Information on how well Isoniazid Preventive Therapy (IPT) works on reducing TB incidence
among people living with HIV (PLHIV) in routine settings using robust statistical methods to
establish causality in observational studies is scarce.
Objectives
To evaluate the effectiveness of IPT in routine clinical settings by comparing TB incidence
between IPT and non-IPT groups.
Methods
We used data from PLHIV enrolled in 315 HIV care and treatment clinic from January 2012
to December 2016. We used Inverse Probability of Treatment Weighting to adjust for the
probability of receiving IPT; balancing the baseline covariates between IPT and non-IPT
groups. The effectiveness of IPT on TB incidence was estimated using Cox regression
using the weighted sample.
Results
Of 171,743 PLHIV enrolled in the clinics over the five years, 10,326 (6.01%) were excluded
leaving 161,417 available for the analysis. Of the 24,800 who received IPT, 1.00% devel-
oped TB disease whereas of the 136,617 who never received IPT 6,085 (4.98%) developed
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TB disease. In 278,545.90 person-years of follow up, a total 7,052 new TB cases were diag-
nosed. Using the weighted sample, the overall TB incidence was 11.57 (95% CI: 11.09–
12.07) per 1,000 person-years. The TB incidence among PLHIV who received IPT was
10.49 (95% CI: 9.11–12.15) per 1,000 person-years and 12.00 (95% CI: 11.69–12.33) per
1,000 person-years in those who never received IPT. After adjusting for other covariates
there was 52% lower risk of developing TB disease among those who received IPT com-
pared to those who never received IPT: aHR = 0.48 (95% CI: 0.40–0.58, P<0.001).
Conclusion
IPT reduced TB incidence by 52% in PLHIV attending routine CTC in Tanzania. IPTW
adjusted the groups for imbalances in the covariates associated with receiving IPT to
achieve comparable groups of IPT and non-IPT. This study has added evidence on the
effectiveness of IPT in routine clinical settings and on the use of IPTW to determine impact
of interventions in observational studies.
Background
Tuberculosis (TB) is a common opportunistic infection among people living with HIV
(PLHIV) [1, 2]. Despite strategies for control and prevention of TB among PLHIV, co-infec-
tion of TB and HIV (TBHIV) is still a public health concern [3–5]. Worldwide in 2018,
862,000 (2.3%) of all PLHIV had TB disease and 30% of all HIV deaths occurred in individuals
with TBHIV co-infection [6, 7]. The African continent accounted for 24% of all TB cases diag-
nosed and was second to Asia in the number of TB cases. Tanzania was ranked among 30
countries in the World with high TB burden [7]. HIV is a known risk for TB especially in the
absence of antiretroviral therapy (ART). The burden of TB among PLHIV in Tanzania was
reported to 16.7 cases per 1000 person-years [8].
Tanzania adopted World Health Organization (WHO) three I’s strategy which comprises
of intensified TB Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and Infection con-
trol and prevention in all clinical settings since 2010 [9]. IPT entails giving an anti-TB drug to
eligible PLHIV for at least 6 months to treat latent TB infection (LTBI); individuals infected
with TB but without TB disease [10, 11]. IPT integration into HIV care and treatment services
in Tanzania started in 2011 starting with high level health facilities as a phased implementation
to lower level health facilities in 2012, so that 50% of care and treatment clinics (CTC) was
implementing IPT by the end of December 2018 [12]. However, routine data from PLHIV
attending CTC in 3 regions in Tanzania documented14% had initiated IPT from 2012–2016
[13] whereas the target was to cover a minimum of 50% of clinic attendees [14].
IPT is a proven public health intervention to reduce TB among PLHIV by treating LTBI,
thus preventing LTBI from developing into TB disease. A systematic review and meta-analysis
from clinical trials have demonstrated a reduction in TB incidence among PLHIV following
IPT ranging from 30% to 74% [4, 15–17].
Moreover, in routine clinical settings have shown a reduction in TB incidence of between
48% and 76% in PLHIV receiving IPT [18–21]. These studies conducted in Ethiopia, Tanzania
and Brazil but did not address the challenges of using observational studies to establish cause-
effect relationship between IPT and TB incidence when IPT is rolled out in routine clinical set-
tings, the baseline characteristics of those initiated on IPT may differ from those who are not
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initiated on IPT. Propensity scores are one way to obtain an unbiased estimate of the effective-
ness of IPT in preventing TB incidence using observational data from routine clinical settings
[22]. This paper reports a secondary analysis of a cohort of PLHIV enrolled in CTC from Janu-
ary 2012 to December 2016 in the three regions in Tanzania. We applied Inverse-Probability
for Treatment Weighting (IPTW)-one of the propensity score approaches to the data in order
to balance baseline characteristics of PLHIV who received and those who never received IPT
[23]. This approach obtained an objective estimate of the impact of IPT intervention on TB
incidence in using observational data from routine clinical settings where randomization of
the intervention is not done.
Methods
Study design and study population
This analysis used routine data from PLHIV enrolled in 315 CTC in three regions of Tanzania
from January 2012 to December 2016.
Study setting
More information regarding the HIV care and treatment program in Tanzania, including the
integration of the TB services in HIV clinics, has been previously Published [24]. Tanzania has
26 regions and the three regions chosen were among those with the highest HIV prevalence
[25]. Since 2012, all health facilities with CTC in Tanzania have implemented ICF and TB
infection control and prevention, with IPT incrementally rolled out across Tanzania. During
every clinic visit, PLHIV were screened for the presence of TB symptoms and signs as part of
ICF. In health facilities where IPT was available, PLHIV who screened TB negative and fulfill
other clinical criteria were initiated on IPT for 6 months to treat latent TB. Those who
screened positive for TB underwent further TB disease diagnosis using diagnostic tests accord-
ing the TB diagnosis algorithm [26]. TB infection control and prevention was another inter-
vention to reduced TB among PLHIV and was implemented in all health facilities in the
country.
Data collection
Detailed information regarding the demographic and clinical data collected in the Tanzania
CTC has been described elsewhere [13, 24, 27]. At every visit to the CTC data were entered
into an electronic database which was collated on a central server at national level. Indepen-
dent variables used in the study namely sex, age, WHO clinical stage, Antiretroviral Therapy
(ART) status, nutritional status, weight, height, enrolment year, health facility type and owner-
ship and region where the client was registered were routinely recorded in the database. The
database also recorded information on IPT initiation and completion dates and on TB screen-
ing and management. This study extracted those demographic and clinical information
including those of TB services using the unique patient identification number for linking clinic
visits. Any PLHIV who had any evidence of LTBI on the first visit to CTC were excluded from
the analysis.
All PLHIV attending CTCs which never implemented IPT throughout the study period was
also excluded from the analysis.
Data analysis
The primary exposure was IPT (IPT and non-IPT) use and TB disease incidence was the out-
come of interest. “IPT” were individuals who were ever initiated on IPT and outcome of
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interest “non-IPT” were those who were never initiated on IPT throughout the study period.
Sex, age, WHO clinical stage, ART status, Body Mass Index (BMI), functional status, health
facility type, health facility ownership, enrolment year and region and were the covariates
needed to be adjusted for in the analysis. Characteristics of PLHIV who received IPT and
those who never received IPT during the study duration were expressed using unweighted
sample. To balance for measured covariates between those who received IPT and those who
never received IPT, IPTW was applied. The following steps were followed in creating weighted
dataset: (1) Selection of covariates which are potential confounders (affecting both IPT initia-
tion and TB disease diagnosis): Sex, age, functional status, ART status, Body Mass Index
(BMI), nutritional status, health facility type, region and health facility ownership (12,19,28)
were selected for propensity score model. (2) Creating Propensity scores (probability of
receiving IPT condition to covariates): As these covariates differed between those who
received IPT and those who never received IPT. Logistic regression was used to calculate pro-
pensity score to estimate the odds of receiving IPT. From the propensity scores, IPTW was cre-
ated for each PLHIV to make a synthetic sample in which IPT and non-IPT groups were
balanced.
The treatment effect to be calculated is Average Treatment Effect (ATE). ATE refers to the
treatment effect to the entire target population (3) Checking for balance after weighting: The
balance between the two groups was determined quantitatively by comparing standardized
means and variances of the 2 groups. Weighted sample had standardized difference of closer
to zero whereas the variance in the weighted group was closer to 1 compared to unweighted
sample, showing covariate balance in the weighted sample [28, 29]. (4) Calculating Propensity
Scores weights: From the propensity scores an IPTW was created for each PLHIV and this
weight was used to make a synthetic sample in which IPT and non-IPT groups were Balanced.
The weighted sample was then used to determine the TB incidence rates and risk factors for
developing TB disease. The weighted dataset was used for the survival analysis using TB dis-
ease diagnosis as the failure variable. Entry time was the first date seen in the CTC (after 1st
January 2012) and exit time out was TB diagnosis date, or the last clinic visit recorded. TB inci-
dence rates and corresponding 95% Confidence Intervals were calculated by dividing the sum
of all TB episodes occurring during follow up and total time contributed by each of the study
participant. For individuals who received IPT the time before receipt of IPT was considered
“not on IPT” and the time following initiation of IPT considered “on IPT”. Risk factors for
developing TB disease among PLHIV were analyzed using regression model. The univariate
Cox-regression model contained covariates either known to influence TB diagnosis from pre-
vious studies or from clinical experience of the authors. Multivariate regression included
covariates with P-values less than 0.2 to obtain adjusted Hazard Ratios (HR) and 95% confi-
dence intervals (95% CI). Multivariate analysis was done to control for possible residual con-
founding despite IPTW [30]. Cluster effect at the health facility level was checked in the
regression model and were not significant. Kaplan Meier graphs for the effect of IPT on TB
incidence were drawn to show comparison of TB disease probabilities between those who
received IPT and those who did not receive IPT. Stata version 14 (College Station, TX: Stata
Corp LP) was used for analysis.
Ethical consideration
To maintain participants’ confidentiality. the study used de-identified routinely collected HIV
data. The data was fully de-identified before made accessible. Ethical review and approval was
granted by Kilimanjaro Christian Medical College (KCMUCo) Institutional Review Board
(IRB) which granted the ethical clearance certificate number 2287. The parent project known
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as SEARCH was given ethical approval by NIMR with approval number National Institute of
Medical Research (NIMR)/HQ/R.8c/Vol.II/961. The submitted manuscript is part of Doctor
of Philosophy work within the main project. As the study used de-identified secondary data
from routine clinical visits, the need for informed consent from the study participants was
waived by both KCMUCo IRB and NIMR ethical approval. Data used for the study can be
available for public use in the research repository of London School of Hygiene and Tropical
Medicine, United Kingdom. The data can be accessed using the following link: https://www.
lshtm.ac.uk/sites/default/files/201706/Tanzania%20CTC%20Documentation.pdf.
Results
(1) Baseline characteristics of study participants
A total of 171,743 PLHIV enrolled in 315 health facilities in Dar es Salaam, Iringa and Njombe
regions from January 2012-December 2016. A total of 10,326 (6.01%) study participants were
excluded from the analysis as they either had TB disease before CTC enrolment or had TB
diagnosed at CTC before follow up or they were from clinics which never implemented IPT
throughout the study period. Of the 161,417 who were involved in the analysis, only 1.00% of
PLHIV developed TB disease among those who received IPT and 4.98% among those who
never received IPT (Fig 1).
Majority of individuals who received IPT were females (71.60%), aged 25–49 years
(77.19%), with working functional status (97.51%), in WHO clinical stage III (33.61%) not on
ART (72.11%), in individuals with normal BMI (57.76%) and in PLHIV with normal nutri-
tional status (93.81%). IPT initiation was also higher among those enrolled in 2014 (22.75%)
Dar es Salaam region (74.72%, enrolled in hospital (49.27%) and enrolled in public health facil-
ities (83.88%) (Table 1).
(2) Balance of covariates after IPTW
After IPTW, the standardized differences for the weighted sample were closer to zero com-
pared to the unweighted sample. The variances of the different covariates were closer to 1 com-
pared to the variance in the unweighted sample.
(Table 2).
(3) TB cases, follow up time and TB incidence rate
During follow up, a total of 7,052 new TB cases were diagnosed with a total of 278,545.90 per-
son years giving an overall TB incidence rate of 25.32 (95% CI: 21.43–30.31) per 1,000 person-
years. Using the weighted sample, an overall TB incidence of 11.57 (95% Confidence Interval
(CI): 11.09–12.07) per 1,000 person-years was obtained. PLHIV who received IPT had lower
TB incidence rate compared with those who never received IPT: 10.49 (95% CI: 9.11–12.15)
per1,000 person-years versus 12.00 per 1,000 (95% CI: 11.69–12.33) per 1,000 person-years
respectively. TB incidence rate was also lower higher among females; 9.27(95% CI: 8.76–9.82
per 1,000 person-years compared to males, in PLHIV aged 20–24 years: 6.10 (95% CI: 4.92–
7.66) compared to other age groups, in PLHIV with working functional status; 11.27 (95% CI:
10.78–11.78) per 1,000 person-years than in other functional statuses and in those who were
on ART: 8.38 (95% CI: 7.45–9.47) per 1,000 person-years compared with those not on ART.
TB incidence was also decreased in those with WHO clinical stage I; 6.05 (95% CI:5.34–6.82)
per 1,000 person-years compared to higher WHO clinical stages in those who were obese: 4.71
(95% CI: 3.59–6.32) per 1,000 person-years compared to those with other weights, in those
with normal nutritional status: 10.83 (95% CI: 10.32–11.37) per 1,000 person-years compared
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to other groups. TB incidence rate was also decreased in PLHIV enrolled in dispensaries: 10.35
(95% CI: 9.44–11.37) per 1,000 person-years compared to those in other health facility levels,
in PLHIV enrolled in care in 2012: 9.20 (95% CI: 8.42–10.06) per 1,000 person-years compared
to those in the following years, in those enrolled in Njombe region: 6.45 (95% CI: 5.77–7.25)
Fig 1. Flow diagram for Isoniazid Preventive Therapy and TB diagnosis among PLHIV. The figure showed only 15.36% of the PLHIV in the study
were initiated on Isoniazid Preventive Therapy. When compared, less PLHIV who ever used IPT developed TB disease (1.00%) than those who did not
use IPT (4.98%).
https://doi.org/10.1371/journal.pone.0254082.g001
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Table 1. Baseline characteristics of study participants, N = 161,417.
Variable IPT status
Never on IPT n = 136,617 Ever on IPT n = 24,800 Total P-value
Sex
Male 42,409 (31.04%) 7,044 (28.40%) 49,453 (30.63%) P<0.001
Female 94,208 (68.96%) 17,756 (71.60%) 111,964 (69.36%)
Baseline age Mean: 33.64 years, SD = 12.44 years, Range: 0–95 years
0–9 6,741(4.93%) 567 (2.29%) 7,308 (4.53%) P<0.001
10–19 6,458 (4.73%) 739 (2.98%) 7,197 (4.46%)
20–24 13,977 (10.23%) 1,808 (7.29%) 15.785 (9.78%)
25–49 96,848 (70.89%) 19,143 (77.19%) 115, 991 (71.86%)
+ 50 12,593 (9.22%) 2,543 (10.25%) 15,136 (9.38%)
Baseline functional status
Ambulatory 4,222 (3.10%) 475 (1.92%) 4,697 (2.92%) P<0.001
Bedridden 1,143 (0.84%) 139 (0.56%) 1,282 (0.80%)
Working 130,642 (96.06%) 24,069 (97.51%) 154,711 (96.28%)
Baseline WHO clinical stage
I 52,176 38.70% 8,175 (33.39%) 60,351 (37.89%) P<0.001
II 32,513 24.12% 6,684 (27.30%) 39,197 (24.61%)
III 40,051 29.71% 8,230 (33.61%) 48,281 (30.21%)
IV 10,073 7.47% 1,398 (5. 71%) 11,471 (7.20%)
Baseline ART status
No ART 85,297 (62.90%) 17,749 (72.11%) 103,046 (64.31%) P<0.001
ART 50,321 (37.10%) 6,865 (27.89%) 57,186 (35.69%)
Baseline BMI
Underweight 14,806 (17.13%) 2,584 (14.18%) 17,390 (16.61%) P<0.001
Normal 48,697 (56.33%) 10,524 (57.76%) 59,221 (6.57%)
Overweight 15,598 (18.04%) 3,465 (19.02%) 19,063 (18.21%)
Obesity 7,356 (8.51%) 1,648 (9.04%) 9,004 (8.60%)
Baseline nutritional status
Normal 120,051 (92.35%) 22,438 (93.81%) 142,489 (92.58%) P<0.001
Moderate 8,501 (6.54%) 1,335 (5.58%) 9,836 (6.39%)
Severe 1,445 (1.11%) 146 (0.61%) 1,591 (1.03%)
CTC enrolment year
2012 24,364 (17.83%) 4,378 (17.65%) 28,742 (17.81%) P<0.001
2013 26,603 (19.47%) 5,017 (20.23%) 31.620 (19.59%)
2014 28,491 (20.85%) 5,643 (22.75%) 34,134 (21.15%)
2015 26,215 (19,19%) 5,031 (20.29%) 31,246 (19.36%)
2016 30,944 (22.65%) 4,731 (19.08%) 35,675 (22.10%)
Region at enrolment
Dar es Salaam 96,524 (70.65%) 18,556 (74.82%) 115,080 (71.29%) P<0.001
Iringa 17,216 (12.60%) 1,238 (4.99%) 18.454 (11.43%)
Njombe 22,877 (16.75%) 5,006 (20.19%) 27,883 (17.27%)
Health Facility Type at enrolment
Dispensary 55,932 (40.94%) 6,232 (25.13%) 62,164 (38.51%) P<0.001
Health Center 36,619 (26.80%) 6,348 (25.60%) 42,967 (26.62%)
Hospital 44,066 (32.26%) 12,220 (49.27%) 56,286 (34.87%)
Health Facility ownership at enrolment
(Continued)
PLOS ONE Impact of Isoniazid Preventive Therapy on Tuberculosis incidence
PLOS ONE | https://doi.org/10.1371/journal.pone.0254082 July 13, 2021 7 / 16
per 1,000 person-years compared to those registered in other regions and in those enrolled in
private health facilities: 10.37 (5% CI:9.24–11.67–10.29) per 1,000 person-years compared to
those enrolled in public health facilities (Table 3).
Kaplan-Meier graph comparing TB disease between those who received IPT and those who
did not use IPT was fitted. With increasing time of follow up cumulative incidence of TB dis-
ease increased in both groups. However, the incidence was higher among those who did not
receive IPT compared with those who received the intervention (Fig 2).
(4) Risk factors for TB disease
In multivariate analysis of unweighted sample, the risk of developing TB disease was less by
13% among those who ever received IPT: adjusted Hazard Ratio (aHR) = 0.87 (95% CI:0.76–
1.01; P>0.05) compared to those who never used IPT. Using weighted sample, after adjusting
for other covariates the risk of TB incidence was reduced by 52% in the IPT group compared
to non-IPT; aHR = 0.48 (95% CI: 0.40–0.58; P<0.001). In the weighted sample, the risk of
developing TB disease was also lower among females: aHR = 0.55 (95% CI: 0.50–0.61),
P<0.001, in those who were obese: aHR = 0.36 (0.26–0.48), P<0.05, in those on ART:
aHR = 0.61 (95% CI:0.53–0.70), P<0.001, and in those enrolled in Njombe region: aHR = 0.28
(95% CI:0.23–0.33), P<0.001. The risk of TB disease was increased in individual with WHO
clinical stage IV; aHR = 3.44 (95% CI: 2.84–4.17), P<0.001 (Table 4).
Discussion
We set out to determine impact of IPT on TB incidence among PLHIV as well show case
the application of IPTW to minimize selection bias in observational studies in order to
Table 1. (Continued)
Variable IPT status
Never on IPT n = 136,617 Ever on IPT n = 24,800 Total P-value
Public 96,211 (70.42%) 20,803 (83.88%) 117,014 (72.49%) P<0.001
Private 40,406 (29.58%) 3,997 (16.12%) 44.403 (27.51%)
95% CI = 95% Confidence Interval, ART = Antiretroviral Treatment, BMI-Body Mass Index, Care and Treatment Clinic, IPT = Isoniazid Preventive Therapy,
TB = Tuberculosis, SD = Standard Deviation, WHO = World Health Organization.
https://doi.org/10.1371/journal.pone.0254082.t001
Table 2. Balance between unweighted and weighted samples after Inverse Probability of Treatment Weighting.
Covariate Standardized Difference Variance
Unweighted sample Weighted sample Unweighted sample Weighted sample
Sex 0.03721 -0.01170 0. 9636 1.0162
Baseline age 0.1489 0.0108 0.7395 0.8963
Baseline functional status 0.8073 -0.0034 0.5981 1.0154
Baseline ART status -0.2385 -0.0019 0.8344 0.9989
Baseline BMI 0.0559 -0.0130 0.9685 0.9502
Baseline nutritional status -0.0736 0.0003 0.7400 0.9962
Health Facility type at enrolment 0.3583 0.0056 0.9118 0. 9695
Region at enrolment 0.0147 0.0123 1.2120 1.1355
Health Facility ownership at enrolment 0.2935 -0.0134 0.5677 1.0206
ART = Antiretroviral Therapy, BMI-Body Mass Index.
https://doi.org/10.1371/journal.pone.0254082.t002
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Table 3. The incidence of TB cases, total person-year and TB rates among 24,800 PLHIV who received IPT and a
weighted sample of those who did not receive IPT.
Variable Number of TB cases Total person-years (Years) Rate/1,000 (95% CI)
Overall 1,037 89,661 11.57 (11.09–12.07)
IPT status
Never on IPT 765 63,739 12.00 (11.69–12.33)
Ever on IPT 272 25,922 10.49 (9.11–12.15)
Sex
Male 450 26,335 17.10 (16.05–18.23)
Female 587 63,327 9.27 (8.76–9.82)
Baseline age
0–19 105 7,442 14.17 (11.68–17.37)
20–24 45 7,427 6.10 (4.92–7.66)
25–49 764 66,226 11.54 (11.03–12.07)
+50 122 8,566 14.27 (12.69–16.11)
Baseline functional status
Ambulatory 54 2,545 21.06 (18.25–24.35)
Bedridden 9 606 14.68 (9.72–23.05)
Working 975 86,511 11.27 (10.78–11.78)
ART status
No on ART 824 64,279 12.82 (12.28–13.40)
ART initiated 209 24,937 8.38 (7.45–9.47)
Baseline WHO clinical stage
Stage I 194 32,060 6.05 (5.34–6.82)
Stage II 232 24,647 6.40 (8.58–10.39)
Stage III 485 26,317 18.43 (17.54–19.39)
Stage IV 119 5,678 21.91 (17.99–24.43)
Baseline Body Mass Index
Underweight 208 9,349 20.25 (20.81–23.81)
Normal 398 33,280 11.95 (11.29–12.36)
Overweight 75 10,888 6.84 (5.94–7.92)
Obesity 25 5,221 4.71 (3.59–6.32)
Baseline nutritional status
Normal 859 79,304 10.83(10.32–11.37)
Moderate 116 5,270 21.95 (19.99–24.14)
Severe 23 784 29.59 (22.58–39.03)
Health Facility type at enrolment
Dispensary 338 32,666 10.35 (9.44–11.37)
Health center 253 23,661 10.70 (9.95–11.02)
Hospital 446 33,334 13.38 (12.66–14.14)
CTC enrolment year
2012 227 24,631 9.20 (8.42–10.06)
2013 230 23,720 9.69 (8.89–10.60)
2014 216 20,767 10.42 (9.55–11.40)
2015 188 13,014 14.45 (13.04–16.06)
2016 176 7,530 23.38 (21.01–26.10)
Region at enrolment
Dar es Salaam 850 62,545 13.60 (13.00–14.23)
Iringa 78 10,323 7.58 (6.08–9.57)
(Continued)
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establish causal relationship between IPT and TB incidence among PLHIV in routine clini-
cal settings.
These results show that in the implementation of IPT the risk of developing TB Disease was
reduced by a half (52%) in those who received IPT in the studied cohort when compared to
those who never received IPT after applying IPTW and adjusting for confounding from other
factors. The results also show lower TB disease incidence among those who received IPT in
comparison with those who never received IPT. Both lower rates of TB among those who ever
used IPT and reduced TB risk among IPT users consolidates evidence of effectiveness of IPT
on TB incidence among PLHIV. Lower TB incidence among IPT users has also been docu-
mented in other studies where PLHIV who ever used IPT had lower rates of TB incidence
than those who never used IPT [4, 18, 31–34], however, unlike many of these studies in real
Table 3. (Continued)
Variable Number of TB cases Total person-years (Years) Rate/1,000 (95% CI)
Njombe 108 16,793 6.45 (5.77–7.25)
Health Facility ownership at enrolment
Private 274 26,420 10.37 (9.24–11.67)
Public 763 63,241 12.07 (11.75–12.79)
95% CI = 95% Confidence Interval, ART = Antiretroviral Treatment, CTC = Care and Treatment Clinic,
IPT = Isoniazid Preventive Therapy, TB = Tuberculosis, WHO = World Health Organization.
https://doi.org/10.1371/journal.pone.0254082.t003
Fig 2. Kaplan Meier graph showing cumulative Tuberculosis incidence depending on the status of Isoniazid Preventive
Therapy. Throughout the follow up, those who ever received IPT had less cumulative Tuberculosis incidence than those who
did not receive the intervention.
https://doi.org/10.1371/journal.pone.0254082.g002
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Table 4. Risk factors for TB disease using weighted sample.
Variable Univariate Multivariate
cHR, 95% CI P-Value aHR, 95% CI P-Value
IPT status
Never on IPT 1 P>0.05 1 P<0.001
Ever on IPT 0.87 (0.76–1.01) 0.48 (0.40–0.58)
Sex
Male 1 P<0.001 1 P<0.001







Underweight 1 P<0.001 1 P<0.001
Normal 0.54 (0.49–0.59) 0.71 (0.64–0.79)
Overweight 0.31 (0.26–0.36) 0.46 (0.38–0.54)






ART not initiated 1 P<0.001 1 P<0.001
ART initiated 0.65 (0.58–0.74) 0.61 (0.53–0.70)
Baseline WHO clinical stage
Stage one 1 P<0.001 1 P<0.001
Stage two 1.55 (1.33–1.81) 1.51 (1.28–1.78)
Stage three 3.04 (2.68–3.46) 3.03 (2.64–3.48)
Stage four 3.45 (2.85–4.18) 3.44 (2.84–4.17)
Nutritional status
Normal 1 1
Moderate 2.03 (1.82–2.26) P<0.001 1.19 (1.05–1.35) P>0.05
Severe 2.73 (2.05–3.65) 1.22 (0.87–1.72)
Health Facility type
Dispensary 1 P>0.05









Dar es Salaam 1 1 P<0.001
Iringa 0.56 (0.44–0.70) P<0.001 0.33 (0.25–0.42)
Njombe 0.47 (0.42–0.54) 0.28 (0.23–0.33)
(Continued)
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life, the current study applied IPTW to minimize bias associated with non-experimental study
designs. Protective effect of IPT on TB incidence among PLHIV in non-research, routine HIV
care settings have also been determined in other studies when those who used IPT were com-
pared with those who did not use in routine settings in Tanzania [20], Ethiopia [4, 18, 34–36]
and a systematic review [16], and it ranged from 48% to 94%. The various studies showed that
the protective effect of IPT is stretched over a long range. These studies were conducted in dif-
ferent routine settings with varying degrees of data quality together with different approaches
in controlling for possible biases during data analysis level. Hence, the range of IPT effective-
ness in these studies could be due to different study settings and different statistical manipula-
tions done to make those who received IPT and those who did not receive comparable groups.
Overall this population had a relatively lower TB incidence reduction compared to other
similar studies in Sub-Saharan Africa including the study in Tanzania [20]. The discrepancy
between our study and other studies could also be due to lack of application of statistical tech-
niques like propensity scores to minimize selection bias associated with observational studies
[23, 29]. Lack of use of such techniques to minimize selection bias in establishing causal infer-
ence in observation studies may result in erroneous estimation of the outcome of interest [37].
The results from the analysis of the weighted data also showed that the risk of TB disease
was also lower among females, those on ART, obese individuals and those enrolled in Njombe
region. The risk of TB disease was higher in PLHIV with baseline WHO clinical stage IV.
Other studies have also shown a low TB risk among females in comparison with Males [38,
39]. Difference in health seeking behavior between males and females [38] and the role of bio-
logical difference between the two sexes playing a role in immune responses in resisting Myco-
bacterium Tuberculosis have been attributed to the differences [39]. ART use is a known public
health tool in reducing the risk of developing TB disease among PLHIV [2, 40, 41]. ART
restores immune responses to Mycobacterium Tuberculosis through lowering of HIV viral load
and hence, prevents HIV-associated TB [41]. Lower TB disease risk among individuals with
higher BMI (overweight and obese) in comparison with normal nutritional status has also
been reported by others [42, 43]. Overweight or obese people may have increased intake of
protein and energy containing food as well as micronutrients which may be protective of TB
diseases [43]. However, a thorough mechanism of the association between nutritional status
and TB disease may be needed. Different TB risk according to regions could be attributed to
health system components which were beyond the scope of this study. Regional variations in
TB disease in Tanzania has also been reported by others [44]. The risk of TB disease in individ-
uals with advanced WHO clinical stages (stage 3 and 4) is also reported in other studies [45,
46]. Advanced HIV affects both cellular and hormonal immune responses required to control
TB, thus increasing TB disease susceptibility in individuals with advanced HIV disease [47].
ICF and IPT in Tanzania were scaled up from 2011. The observed increased TB notification
with increasing years from 2012 could be due to scaling up of these interventions which result
Table 4. (Continued)
Variable Univariate Multivariate
cHR, 95% CI P-Value aHR, 95% CI P-Value
Health facility ownership
Private 1 1 P>0.05
Public 1.16 (1.03–1.32) P<0.001 0.89 (0.75–1.11)
95% CI = 95% Confidence Interval, aHR = Adjusted Hazard Ratio, ART = Antiretroviral Treatment, BMI-Body Mass Index, Care and Treatment Clinic, cHR = Crude
Hazard Ratio, CTC = Care and Treatment Clinic, IPT = Isoniazid Preventive Therapy, TB = Tuberculosis, WHO = World Health Organization.
https://doi.org/10.1371/journal.pone.0254082.t004
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into increased TB case notification [48]. TB diagnosis especially by using Florescent Light
Emitting Diode (LED) microscopy and Gene-Xpert has been improved over time. Use of these
diagnostic tests which perform better than conventional light microscopy lead to increased TB
case notification [49, 50]. Moreover, the fact that advancement in TB diagnosis happened as
years go, this may explain the increased TB notification from 2012 to 2016. Differences in TB
burden among regions in Tanzania was also documented by others [51]. Different TB burden
among regions together with differences in TB diagnosis among regions in the country may
explain different TB incidence found in this study. Lower TB notification in private health
facilities reported in the current research is similar to those reported by others [52]. This may
be due to less engagement of private health facilities in TB disease management [53].
This study has an implication on practice and policy in preventing TB. The findings of this
study have added information on how IPT works in reducing TB diseases among PLHIV in
routine real-world settings. Such findings encourage policy makers to continue safeguarding
policies on TB preventive strategy. The findings also encourage health care providers to con-
tinue scaling up IPT such that it is accessed by all eligible PLHIV in the country.
The strength of this analysis is that the data are taken from routine visits by PLHIV attend-
ing CTC and hence the results represent the effect of IPT under routine settings. The data
came from three regions representing a cross section of Tanzania where the prevalence was
high [25]. The analysis used IPTW to adjust for the characteristics of study participants [23].
The main limitation of the study as a result of its being a retrospective design, is its inability
to include other variables which could be included as possible confounders for IPT initiation.
These are such as availability of Isoniazid tablets in the health facilities which may affect IPT
initiation. Another limitation of the study is its inability to complete quantitative data with
qualitative data to understand context of IPT delivery. Moreover, the study may result into
overestimating TB among non-IPT recipients because much TB may have been diagnosed
more at the beginning of follow up.
Conclusion
The study found that IPT reduced TB disease in routine HIV care and treatment settings in
Tanzania to the same extent as other studies in routine settings. This study has also shown the
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